The invention provides a novel nuclide-labeled mAb109 monoclonal antibody drug. The monoclonal antibody drug is obtained by coupling a monoclonal antibody mAb109 with a bifunctional chelating agent NCS-Bz-DOTA or NCS-Bz-NOTA and then carrying out radionuclide labeling, wherein the radionuclides comprise all the radionuclides which can be coordinated with a DOTA or NOTA structure. According to the invention, the monoclonal antibody mAb109 with relatively strong Prx1 receptor affinity and relatively good research foundation is taken as a maternal body and is coupled with the bifunctional chelating agent, so that a labeling precursor DOTA-mAb109 or NOTA-mAb109 which can be applied to Prx1 receptor targeting can be obtained; and radionuclides with different properties are respectively used for labeling, so that diagnosis and treatment on Prx1 receptor highly-expressed tumor are carried out. The nuclide-labeled mAb109 monoclonal antibody drug can be specifically combined with Prx1 widely expressed in a body of a solid tumor patient; and by virtue of properties of various nuclides, the aim of in vivo targeting molecule diagnosis and treatment is realized, and the goals of early detection, early diagnosis and early treatment of a solid tumor are achieved.